About the GMP Unit

CellGENTherapies was founded in 2014. In 2016 the first ATMP was produced under GMP conditions. Ever since, the activity has been growing and other technologies became part of the portfolio. CellGENTherapies is currently licensed for the production of investigational advanced therapy medicinal products and and is currently applying for a license for the production of microbial vaccines. 

To house the expanding activities, a new GMP unit will be constructed on the site of UZ Gent (Ghent University Hospital) and should be fully operational by end of 2026.

Our location on the campus of Ghent University Hospital ensures synergies with both the hospital and Ghent University. It also benefits from Ghent’s reputation as a leading cluster for biotech and medical companies, and its position as a gateway to Europe and the world.

Get in touch

Advisory board

Prof. Viggo Van Tendeloo

Johnson & Johnson, external innovation lead & strategic alliances
Viggo Van Tendeloo | LinkedIn

Prof. Karine Breckpot

VUB Translational Oncology Resarch Centre
Karine Breckpot | Translational Oncology Research Centre

Prof. Bieke BROUX

Uhasselt, Research Group Immunology and Infection
Bieke Broux – UHasselt

Prof. Els Henckaerts

KUL Trellis Research Group
Els Henckaerts | Trellis Research Lab

Dr. Robrecht Lembrechts

Kom op tegen Kanker, expert biomedical research funding
Robrecht Lembrechts | Kom op tegen Kanker

Prof. Nathalie Cools

UA IRiS research group and Co-founder Anicells
About Nathalie Cools | University of Antwerp

Prof. Sylvie Rottey

UZGent head of D.R.U.G. and CRIG group leader
Sylvie Rottey (MD, PhD) | CRIG

Prof. Bruno Verhasselt

UZGent Department Human Body Materials
Bruno Verhasselt | UZ Gent